Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Journal article
Curigliano G. et al, (2023), Br J Cancer, 128
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Journal article
Taylor CA. et al, (2022), Nat Med
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Journal article
Curigliano G. et al, (2022), Br J Cancer
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Journal article
Horgan D. et al, (2022), Healthcare (Basel), 10
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Journal article
Larkin J. et al, (2022), Eur J Cancer, 173, 285 - 296
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.
Journal article
Garg M. et al, (2022), Nat Commun, 13
VCAM-1-targeted magnetic resonance imaging improves detection of the tumor-brain interface.
Journal article
Cheng VWT. et al, (2022), Clin Cancer Res
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Journal article
Weber JS. et al, (2021), Eur J Cancer
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.
Journal article
Watson RA. et al, (2021), Sci Immunol, 6
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer
Journal article
SIVAKUMAR S. et al, (2021), Molecular Biomarkers and Precision Medicine for Pancreatic, Liver and Biliary Tract Cancers
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Journal article
Dalle S. et al, (2021), BMC Cancer
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Journal article
Dalle S. et al, (2021), BMC Cancer
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Journal article
Ye W. et al, (2021), Br J Cancer
Tumour gene expression signature in primary melanoma predicts long-term outcomes
Journal article
Garg M. et al, (2021), Nature Communications
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
Journal article
Fane ME. et al, (2020), Clin Cancer Res
Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.
Journal article
Middleton MR. et al, (2020), Clin Cancer Res
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Journal article
Middleton MR. et al, (2020), Br J Cancer
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Journal article
Cheung VTF. et al, (2020), Br J Cancer, 123, 207 - 215
Immune responses in pancreatic cancer may be restricted by prevalence of activated regulatory T-cells, dysfunctional CD8+ T-cells, and senescent T-cells
Journal article
Sivakumar S. et al, (2020), Biorxiv
ctDNA monitoring using patient-specific sequencing and integration of variant reads.
Journal article
Wan JCM. et al, (2020), Sci Transl Med, 12